Biobeat Launches Wearable Continuous Ambulatory Blood Pressure Monitoring Device

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today the launch of its new wearable and continuous ambulatory blood pressure monitoring (ABPM) chest-monitoring device. New Clinical Data Supports Use of Biobeat ABPM Cuffless-Monitor as Reliable and Accurate Solution for Out-of-Clinic Blood Pressure Monitoring

As blood pressure (BP) measurement has shown to be crucial in the early detection and prevention of clinical disorders, ABPM can act as a decisive indicator of patient health, tracking patient cardiac data continuously in real-life settings outside of the physician’s office to provide an accurate, holistic and unbiased view of patient health.

Biobeat’s ABPM solution is currently the only cuffless ABPM application in the world; in addition to retaining patient comfort while enabling the continuation of uninterrupted daily lifestyle, this solution revolutionizes the logistical workflow of the ABPM test, as each disposable, sterile monitor is delivered directly to the patient’s home via courier.

“As healthcare continues its digital transformation, the use of ABPM technologies has become increasingly ubiquitous across the healthcare spectrum, and will continue its growth trajectory as we venture further into the post-COVID-19 era,” said Arik Ben Ishay, CEO of Biobeat. “Biobeat is excited to support this positive trend with our new wearable ABPM solution, giving providers a continuous and accurate real-life view into patient cardiac health, replacing antiquated cuff-based technology.”

Biobeat’s disposable wearable chest-monitor includes an easy and intuitive patient self-set-up, requiring no assistance from a clinician or technician. The device measures diastolic and systolic BP, as well as heart rate, mean arterial pressure, cardiac output, and systemic vascular resistance. Measurements are accessible via the patient’s mobile phone via a designated app, and are also readily available for physicians through an online report-analysis web-application. By utilizing the wide range of vital signs measured by the Biobeat device, the report enables health care providers to gain a profound understanding of the root cause of the issues identified and truly personalize medicine, allowing for more precise prescription and titration of medications and therapies.

The new product launch is supported by a recently published peer-reviewed clinical studyThe study, which compared Biobeat’s wearable wrist-monitoring device to a standard cuff-based ABPM device, found that Biobeat’s device has ABPM monitoring capabilities comparable to the standard cuff-based ABPM device. Findings also demonstrated standard cuff-based ABPM devices resulted in higher blood pressure values, likely due to a startle effect resulting from the inflating cuff, and that Biobeat’s wireless wrist monitor caused significantly less inconvenience compared to the cuff-based device. Additionally, the study demonstrated a 24-hour bias of -1.1 mmHg for both diastolic blood pressure (DBP) and systolic blood pressure (SBP), with a mean daytime bias of -1.9 mmHg for DBP and SBP, and an even smaller nighttime bias was determined.

“In addition to systolic and diastolic BP, Biobeat’s novel ABPM device measures cardiac output, stroke volume, heart rate, mean arterial pressure, and systemic vascular resistance, providing a comprehensive clinical understanding of an individual’s health status,” added Professor Arik Eisenkraft, MD, Chief Medical Officer of Biobeat. “This clinical study highlights the benefit of our device over commonly-used cuff-based ABPM devices, with a remarkable ease-of-use and lack of bias resulting from the mechanical effects of the inflating cuff.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles